SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

BioNTechs latest Phase 3 breast-cancer results are drawing attention: the drug met its primary endpoint but delivered only a modest benefit versus chemotherapy, with higher lung-inflammation rates. Traders are debating whether this and an earlier cancer-trial setback signal broader pipeline weakness or are outweighed by other oncology programs and an upcoming pipeline update.

Twilio, Inc. engages in the development of communications software, cloud-based platforms, and services. It operates through Twilio Communications and Twilio Segments. The Twilio Communications segment includes the platforms Messaging and Voice. The Twilio Segment involves Segment, Engage, Flex, Email, and others. The company was founded by John Wolthuis, Jeffery G. Lawson, and Evan Cooke in March 2008 and is headquartered in San Francisco, CA.

Twilio Inc - Ordinary Shares Class A

Twilio Inc

Twilios quarterly results beat expectations and lifted its full-year outlook, but a softer next-quarter organic growth forecast signaled deceleration and drove a sharp selloff. Traders are debating whether slowing messaging growth and weaker customer expansion outweigh the strong results, while some see the pullback as a potential bounce opportunity.

Schwab Strategic Trust - Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF

SCHD is drawing attention as traders discuss a shift from volatile technology and growth stocks toward dividend-paying value and defensive holdings amid market uncertainty. Many point to its recent strength and keep accumulating, while others question its yield and warn that rising Treasury yields or a return to tech could weigh on the fund.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Traders are focused on whether Q3 results will show that oral Wegovy demand and international expansion can offset concerns about Eli Lillys competitive lead in GLP-1 drugs. The community is divided: some see the pill rollout and low valuation as recovery potential, while others remain cautious about Novos execution, management and pipeline; the Hengrui licensing deal also drew debate as a longer-term pipeline move.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvanas Q3 report and disclosure that the SEC closed its investigation without recommending enforcement action drove a sharp rally, with traders also pointing to record sales volumes. The move has fueled short-squeeze and momentum talk, while bears argue that an EPS miss, declining per-car margins and the end of numerical guidance undermine the growth story.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A sharp breakout to a fresh 52-week high has put TGTX in focus, with traders pointing to BRIUMVIs commercial growth and anticipation of earnings and upcoming subcutaneous data. Buyout and short-squeeze theories are circulating, but remain speculation; others see the rally as momentum ahead of those catalysts.

Almonty Industries, Inc. engages in the mining, processing, and shipment of tungsten concentrates. Its projects include Almonty Korea Tungsten, Panasquiera mine, Gentung, Almonty Korea Moly, Los Santos mine, and Valtreixal. The company was founded on September 28, 2009 and is headquartered in Dillon, MT.

Almonty Industries Inc

A sharp selloff and persistent volatility dominate discussion, with traders pointing to broader weakness in miners and uncertainty over Sangdongs production ramp and near-term cash flows. Some remain bullish on tungsten-market fundamentals and the mines first shipment, while others say the investor-day discussion offered little new detail and are concerned about execution.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Amgens run to recent highs has traders focused on its upcoming quarterly results, with options activity drawing attention; some view put buying as protection ahead of the report rather than a bearish bet. Optimism around the companys recent positive IMDELLTRA lung-cancer trial results also supports the pipeline discussion.

Crown Castle, Inc. engages in the business of owning, operating, and leasing shared communications infrastructure. It operates through the following segments: Towers, Fiber, and Other. The Towers segment focuses on providing coverage and capacity for wireless carrier network deployments. The Fiber segment includes communications infrastructure offerings of small cells and fiber solutions. The Other segment is involved in corporate assets such as cash and cash equivalents. The company was founded by Ted B. Miller Jr. and Edward C. Hutcheson Jr. in 1994 and is headquartered in Houston, TX.

Crown Castle Inc

Crown Castle International Corp

Reports that SpaceX is in talks to access at least 80,000 U.S. cell sites, including Crown Castles towers, have focused attention on the prospect of a major new leasing customer. Traders see potential tower revenue upside, while skeptics note that no agreement is signed and question whether SpaceXs wireless plans will translate into meaningful demand.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Oktas earnings beat and raised outlook fueled a sharp rally, with traders betting that AI-agent adoption will lift demand for identity security. The bullish AI-security thesis is being weighed against concerns that the stocks run has stretched its valuation, prompting profit-taking and calls for a pullback.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Electromed, Inc. (ELMD) Surpasses Q4 Earnings Estimates

Electromed (ELMD) delivered earnings and revenue surprises of +21.88% and -2.43%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

InspireMD, Inc. (NSPR) Reports Q2 Loss, Beats Revenue Estimates

InspireMD (NSPR) delivered earnings and revenue surprises of +15.00% and +7.33%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Lucid Diagnostics Inc. (LUCD) Reports Q2 Loss, Lags Revenue Estimates

Lucid Diagnostics (LUCD) delivered earnings and revenue surprises of -50.00% and -1.73%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

DarioHealth Corp. (DRIO) Reports Q2 Loss, Lags Revenue Estimates

DarioHealth (DRIO) delivered earnings and revenue surprises of +25.00% and -16.37%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Envoy Medical, Inc. (COCH) Reports Q2 Loss, Misses Revenue Estimates

Envoy Medical, Inc. (COCH) delivered earnings and revenue surprises of +22.22% and -15.00%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Senseonics Holdings (SENS) Reports Q2 Loss, Tops Revenue Estimates

Senseonics (SENS) delivered earnings and revenue surprises of -14.55% and +10.73%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

4 Low-Beta Stocks to Minimize Portfolio Risk: LQDA, FLXS, ELMD & AGX

LQDA, FLXS, ELMD and AGX combine low beta, positive price momentum and strong fundamentals to help investors navigate market volatility.

Electromed (ELMD) Is a Great Choice for 'Trend' Investors, Here's Why  

Electromed (ELMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

ELV Accelerates Clinical Reviews Through Health OS Platform

Elevance Health's Health OS is cutting review delays and admin work, with early results showing fewer denials and holds as digital healthcare adoption expands.

Here's Why Momentum in Electromed (ELMD) Should Keep going

If you are looking for stocks that are well positioned to maintain their recent uptrend, Electromed (ELMD) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Electromed, Inc. engages in the development, manufacturing, marketing, and sale of medical equipment. The firm's products include SmartVest SQL System and SmartVest Connect. It focuses on building market awareness, and acceptance of its products and services with physicians, clinicians, patients, and third-party payers. The company was founded by Robert D. Hansen and Craig N. Hansen in 1992 and is headquartered in New Prague, MN.

Electromed Inc.

Why Electromed Stock Jumped 12% After-Hours: A Rival’s Weakness And A New Drug Tailwind

Equity

Bullish Sentiment

Electromed traded higher after hours on Tuesday as management highlighted hospital market share gains from a “distracted rival”, a strategy they credited with contributing to the company’s 11th straight quarter of year-over-year revenue and profit growth.The stock closed up 2.3% at $20.66 on Tuesday and jumped another 12.6% after hours following its earnings release.The maker of the SmartVest airway clearance system reported record fourth-quarter revenue of $17.4 million, up 17% from last year, as profit rose 21% to $2.2 million, or $0.25 a share.&nbsp;On the earnings call, Electromed detailed growth drivers beyond the headline numbers. Executives said hospitals are proving to be a “gateway” channel as patients introduced to SmartVest in care settings are often discharged with prescriptions for home use.&nbsp;CEO Jim Cunniff added that a major competitor with an “older product” is internally distracted, creating opportunities for market share growth.The company also highlighted strong e-prescribe adoption, with 38% of orders now submitted digitally, resulting in a halving of&nbsp;fulfillment times. A new Salesforce-based CRM integrating sales and reimbursement teams has also been rolled out, earning positive early feedback.&nbsp;Productivity gains continue, with sales&nbsp;representatives averaging $1.06 million each in annual revenue, up from $850,000 three years ago. Expansion to 61 territories is planned for FY26.Electromed is also benefiting from greater awareness of bronchiectasis after Insmed’s new drug launch, which executives said is raising disease visibility without competing on airway clearance.&nbsp;Earlier this month, the U.S. Food and Drug Administration (FDA)&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/insmed-announces-fda-approval-for-drug-to-treat-chronic-lung-disease/chrxJPSRdJk">approved Insmed’s Brinsupri</a>, an oral once-daily treatment, as the first and only FDA-approved therapy for non-cystic fibrosis bronchiectasis (NCFB).&nbsp;The drug is cleared for use in adults and children aged 12 and older.&nbsp;Electromed noted over 31,000 visits to its bronchiectasis campaign site and cited registry data showing 58% of patients meeting criteria for HFCWO therapy remain untreated, a gap it sees as a major market opportunity.On Stocktwits, retail sentiment for Electromed was ‘bullish’ amid ‘high’ message volume.<a href="https://stocktwits.com/symbol/ELMD">Electromed’s stock</a> has declined over 30% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Electromed’s stock (ELMD) has declined over 30% so far in 2025. (Photo credit: Getty Images)

The after-hours surge came as management pointed to hospital market share gains from a distracted competitor and rising bronchiectasis awareness following Insmed’s FDA-approved drug launch.

Insmed Inc

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$27.04
Prev Close	$27.68
Open	$27.95
Dividend Yield	0.00%
50-Day Moving Average	$28.37
Beta	0.72
Avg. Volume	103,284.88
PE Ratio	20.79

52-Week High	$47.40
52-Week Low	$23.01
Market Capitalization	$224.08M
EPS (Annual)	$1.30
Price to Book	4.19
Revenue Per Employee	$374,497.46

Feed

News

Sentiment

Earnings

Fundamentals

Info

ELMD Fundamentals